Active — Not RecruitingEarly Phase 1

Adiposity and Endothelin Receptor Function

United States25 participantsStarted 2018-05-21

Plain-language summary

Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.

Who can participate

Age range18 Years – 40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: • If you are an adult between the ages of 18-40 year old Exclusion Criteria: * Evidence of cardiovascular, pulmonary, renal, hepatic, cerebral, or metabolic disease * Evidence of pregnancy * Using medications that affect vascular tone (i.e., nitrates, etc.) * Use of any anticoagulants (i.e. aspirin) * Anemia * If you are postmenopausal * If you have uncontrolled hypertension (treated resting SBP \>140 mm Hg or DBP \>90 mm Hg)

What they're measuring

Percentage Change in Flow-Mediated Dilation (FMD)

Timeframe: pre-treatment Baseline and 7 days post-treatment

Trial details

NCT IDNCT03583866

SponsorAugusta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12

View on ClinicalTrials.gov More Hypertension trials